# US 6,727,282 B2 · Succinoylamino hydroxyethylamino sulfonamides useful as retroviral protease inhibitors

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 6,727,282 B2
- Document ID: US6727282B2
- Status: Granted
- Kind: B2
- Application number: 10/237,184
- Filed: 2002-09-09
- Published: 2003-11-27
- Granted: 2004-04-27
- Earliest claimed: 1992-08-25
- Assignees: G.D. Searle & Co.
- Inventors: Michael L. Vazquez; Richard A. Mueller; John J. Talley; Daniel Getman; Gary A. DeCrescenzo; John N. Freskos
- Web page: https://patentgrep.com/patent/US6727282B2

## CPC

- C07C 311/05: to acyclic carbon atoms of hydrocarbon radicals substituted by nitrogen atoms, not being part of nitro or nitroso groups
- C07C 311/18: to an acyclic carbon atom of a hydrocarbon radical substituted by nitrogen atoms, not being part of nitro or nitroso groups
- C07C 311/29: having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
- C07C: ACYCLIC OR CARBOCYCLIC COMPOUNDS

## Abstract

Succinoylamino hydroxyethylamino sulfonamide compounds are effective as retroviral protease inhibitors, and in particular as inhibitors of HIV protease.

## Claims

### Claim 1

A compound represented by the formula:
or a pharmaceutically acceptable salt or ester thereof, wherein:
x represents 0, 1 or 2;
t represents either 0 or 1;
X′ represents —N(R34)— or —O—; or R33—X′— represents cycloalkyl or aryl radicals; Y and Y ′ each independently represents O or S;
R1, R30, R31 and R32 each independently represent hydrogen, —OH, —(CH2)C(O)CH2, —CH2SO2NH2, —CO2CH3, —CONHCH3, —CON(CH3)2, —CH2C(O)NHCH3, —CH2C(O)N(CH3) 2, —CONH2, —C(CH3)2(SH)3—C(CH3)7(SCH1), —C(CH3)2(S(O)CH3), —C(CH3)2(S(O)3CH3), alkyl, haloakyl, alkenyl, alkynyl, aralkyl or cycloakyl radicals or the side chain of the amino acid asparagine, S-methyl cysteine or the corresponding sulfoxide or sulfoxide derivatives thereof, leucine, isoleucine, allo-isoleucine, tert-leucine, phenylalanine, omithine, alanine, norleucine, glutamine, valine, threonine, serine, o-alkyl serine, aspartic acid, beta-cyno alanine or allothreonine; or R30 and R32 together with the carbon atoms to which they are attached form a cycloalkyl radical;
R2 represents alkyl, aryl, cycloalkyl, cycloalkylalky or aralkyl radicals, which radicals are optionally substituted with halogen, alkyl, —NO2, —CN, —CF3, —OR9 or —SR9 radicals, wherein R9 represents hydrogen or alkyl radicals;
R3, R33, and R34 each independently represent hydrogen, alkyl, haloakyl, alkenyl, alkynyl, hydroxyalkyl, alkoxyalkyl, cycloalkyl, cycloalkylalkyl, aryl, aralkyl or aminoalkyl radicals or N-mono- or N,N-disubstituted aminoalkyl radicals, wherein said substituents are alkyl, aryl, aralkyl, cycloalkyl or cycloalkylalkyl radicals;
R4 represents alkyl, haloalkyl, alkenyl, alkynyl, hydroxyalkyl, alkoxyalkyl, cycloalkyl, cycloalkylalkyl, hetercycloalkyl, heteroaryl, heterocycloalkylalkyl, aryl, aralkyl, heteroaralkyl, aminoalkyl, or aryl or aralkyl radicals substituted with one or more substituents selected from alkyl, alkoxy, halogen, hydroxy, amino, nitro, cyano, and haloalkyl;
R4 represents hydrogen or alkyl radicals; and
wherein alkyl, alone or in combination, means a straight-chain or branched-chain alkyl radical containing from 1 to 8 carbon atoms; alkenyl, alone or in combination. means a straight-chain or branched-chain hydrocarborn radial having one or more double bonds and containing from 2 to 8 carbon atoms; alkynyl, alone or in combinaticm, means a straight-chain hydrocarbon radical having one or more triple bonds and containing from 2 to 10 carbon atoms; cycloalkyl, alone or in combination, means a saturated or partially saturated monocyclic, bicyclic or tricyclic alkyl radical wherein each cyclic moiety contains from 3 to 8 carbon atoms; and aryl, alone or in combination, means a phenyl or napbthyl radical which is optionally substituted with one or more alkyl, alkoxy, halogen, hydroxy, amino, acetylamino, nitro, cyano or haloalkyl radicals.

### Claim 2 (depends on 1)

The compound of claim 1 represented by the formula:
or a pharmaceutically acceptcblc salt or ester thereof, wherein:
t represents either 0 or 1;
X′ represents —N(R34)— or —O—; or R33—X′— represents cycloalkyl or aryl radicals;
R1, R30, R31 and R32 each independently represent hydrogen, —OH, —(CH2)C(O)CH2, —CH2SO2NH2, —CO2CH3, —CONHCH3, —CON(CH3)2, —CH2C(O)NHCH3, —CH2C(O)N(CH3)2, —CONH2, —C(CH3)2(SH)3 —C(CH3)2(SCH3), —C(CH3)2(S(O)CH3), —C(CH3)2(S(O)3CH3), alkyl, haloakyl, alkenyl, alkynyl, aralkyl or cycloakyl radicals or the side chain of the amino acid asparagine, S-methyl cysteine or the corresponding sulfoxide or sulfoxide derivatives thereof, leucine, isoleucine, allo-isoleucine, tert-leucine, phenylalanine, omithine, alanine, norleucine, glutamine, valine, threonine, serine, o-alkyl serine, aspartic acid, beta-cyno alanine or allothreonine; or R30 and R32 together with the carbon atoms to which they are attached form a three to six-membered cycloalkyl radical;
R2 represents alkyl, aryl, cycloalkyl, cycloalkylalky or aralkyl radicals, which radicals are optionally substituted with halogen, alkyl, —NO2, —CN, —CF3, —OR9 or —SR9 radicals, wherein R3 represents hydrogen or alkyl radicals;
R3, R33, and R34 each independently represent hydrogen, alkyl, haloakyl, alkenyl, alkynyl, hydroxyalkyl, alkoxyalkyl, cycloaikyl, cycloalkylalkyl, aryl, aralkyl or aminoalkyl radicals or N-mono- or N,N-disubstituted aminoalkyl radicals, wherein said substituents are alkyl, aryl, aralkyl, cycloalkyl or cycloalkylalkyl radicals; and
R4 represents alkyl, haloalkyl, alkenyl, alkynyl, hydroxyalkyl, alkoxyalkyl, cycloalkyl, cycloalkylalkyl, hetercycloalkyl, heteroaryl, hderocycloalkylalkyl, aryl, aralkyl, heteroaralkyl, aminoalkyl, or aryl or aralkyl radicals substituted with one or more substituents selected from alkyl, alkoxy, halogen, hydroxy, amino, nitro, cyano, and haloalkyl.

### Claim 3 (depends on 2)

A pharmaceutically composition comprising the compound of claim 2 and a pharmaceutically acceptable carrier.

### Claim 4 (depends on 2)

The compound claim 2, or a pharamaceutically acceptable salt or ester thereof, wherein t represents either 0 or 1;
X′ represents —O—;
R3, R30, R31 and R32 each independently represent hydrogen, —OH, —(CH2)C(O)CH2, —CH2SO2NH2, —CONHCH3, —CON(CH3)2, —CH2C(O)NHCH3, —CH2C(O)N(CH3)2, —CONH2, —C(CH3)2(SH)3—C(CH3)7(SCH1), —C(CH3)2(S(O)CH3), —C(CH3)2(S(O)2CH3), alkyl, alkenyl, alkynyl or aralkyl radicals, or R30 and R32 together with the carbon atoms to which they are attached form a three to six-membered cycloakyl radical;
R1 represents alkyl, cycloalkylalkyl or aralkyl radicals; which radicals are optionally substituted with halogen, —OR9 or —SR9 radicals, wherein R9 represents hydrogen or alkyl radicals;
R3 represents alkyl, haloalkyl, alkenyl, hydroxyalkyl, alkoxyalkyl, cycloalkyl, cycloalkyLalkyl, aryl or aralkyl radicals;
R4 represents alkyl, haloalkyl, alkenyl, hydroxyalkyl, alkoxyalkyl, cyecloalkyl, cycloalkylalkyl, heteroaryl, aryl, aralkyl, or aryl or aralkyl radicals substituted with one or more substituents selected from alkyl, alkoxy, halogen, hydroxy, amino, nitro, cyano, and haloalkyl; and
R33 represents hydrogen, alkyl, haloalkyl, alkenyl, hydroxyalkyl, alkoxyalkyl, cycloalkyl, cycloalkylalkyl, aryl or aralkyl radicals.

### Claim 5 (depends on 4)

The compound of claim 4, or a pharmaceutically acceptable salt or ester thereof, wherein t is 0;
X represents —O—;
R3, R30, R31 and R32 each independently represent hydrogen, —OH, —(CH2)C(O)CH2, —CH2SO2NH2, —CONHCH3, —CON(CH3)2, —CH2C(O)NHCH3, —CH2C(O)N(CH3)2, —CONH2, —C(CH3)2(SH)3—C(CH3)2(SCH2), —C(CH3)2(S(O)CH3), —C(CH3)2(S(O)2CH3), alkyl, alkenyl, alkynyl or aralkyl radicals;
R3 represents alkyl, cycloalkylalkyl or aralkyl radicals, which radicals are optionally substituted with halogen, —OR9 or S9 radicals, wherein R9 represents hydrogen or methyl radicals;
R9 represents alkyl, haloalkyl, aikenyl, hydroxyalkyl, alkoxyalkyl, cycloalkyl, cycloalkylalkyl, aryl or aralkyl radicals;
R4 represents alkyl, haloalkyl, alkenyl, hydroxyalkyl, alkoxyalkyl, cyecloalkyl, cycloalkylalkyl, heteroaryl, aryl, aralkyl, or aryl or aralkyl radicals substituted with one or more substituents selected from alkyl, alkoxy, halogen, hydroxy, amino, nitro, cyano, and haloalkyl; and
R33 represents hydrogen, alkyl, cycloalkylalkyl or aralkyl radicals.

### Claim 6 (depends on 5)

The compound of claim 5, or a pharmaceutically acceptable salt or ester thereof, wherein t is 0;
X′ represents —O—;
R1, R30, R31 and R32 each independently represent hydrogen or alkyl radicals;
R2 represents alkyl, cycloalkylalkyl or aralkyl radicals, which radicals are optionally substituted with halogen, —OR9 or SR9 radicals, wherein R9 represents hydrogen or methyl radicals;
R3 represents alkyl, cycloalkyl, cycloalkyalkyl, aryl or aralkyl radicals;
R4 represents heteroaryl, aryl, aralkyl, or aryl or aralkyl radicals substituted with one or more substituents selected from alkyl, alkoxy, halogen, hydroxy, amino, nitro, cyano, and haloalkyl alkyl or aryl radicals; and
R33 represents hydrogen, alkyl or aralkyl radicals.

### Claim 7 (depends on 6)

The compound of claim 6, or a pharmaceutically acceptable salt or ester thereof, whercin t is 0;
X′ represents —O—;
R1, R30, R31 and R32 each independently represent hydrogen, methyl or ethyl radicals;
R2 represents CH3SCH2CH2—, n-butyl, benzyl, 4-fluorobenzyl, 2-naphthylmethyl or cyclohexcylmethyl radicals;
R3 represents n-pentyl, n-hexyl, n-propyl, i-butyl, neo-pentyl, i-amyl, n-butyl, benzyl, para-fluombcnzyl, para-methoxybenzyl, para-methylbenzyl, 2-naphthylmethyl, cylohexylmethyl or cyclohexyl radicals;
R4 represents heteroaryl, aryl, or aryl substituted with one or more substituents selected from alkoxy, hydroxy, amino, nitro, cyano, and haloalkyl alkyl or aryl radicals; and
R33 represents hydrogen, methyl, benzyl or (4-methoxyphenyl)methyl radicals.

### Claim 8 (depends on 7)

The compound of claim 7 wherein R4 represents heteroaryl, aryl, or aryl substituted with one or more substituents selected from alkoxy, amino, or nitro radicals.

### Claim 9 (depends on 8)

The compound of claim 8 wherein R31 is hydrogen or methyl.

### Claim 10 (depends on 9)

The compound of claim 9 which is

### Claim 11 (depends on 1)

The compound of claim 1 represented by the formula:
or a pharniaccutically acceptable salt prodrug or ester thereof, wherein
represents either 0 or 1;
Y and Y′ each independently represent O or S;
R1, R30, R31 and R32 each independently represent hydrogen, —OH, —(CH2)C(O)CH2, —CH2SO2NH2, —CO2CH3, —CONHCH3, —CON(CH3)2, —CH2C(O)NHCH3, —CH2C(O)N(CH3)2, —CONH2, —C(CH3)2(SH)3 —C(CH3)2(SCH3), —C(CH3)2(S(O)CH3), —C(CH3)2(S(O)3CH3), alkyl, haloakyl, alkenyl, alkynyl or cycloalkyl radicals, or the side chain of the amino acid asparagine, S-methyl cysteine or the corresponding sulfoxide or sulfone derivatives thereof, leucine, isoleucine, allo-isoleucine, tert-leucine, phenylalanine, omithine, alanine, norleucine, glutamine, valine, threonine, serine, aspartic acid, beta-cyano alanine or allotheonine; or R34 and R32 together with the carbon atoms to which they are attached form a cycloalkyl radical;
R2 represents alkyl, aryl, cycloalkyl, cycloalkylalkyl or aralkyl radicals, which radicals are optionally substituted with halogen, alkyl, —NO2, —CN, —CF3, —OR9 or —SR9 radicals, wherein R9 represents hydrogen or alkyl radicals;
R1, R33, and R34 each independently represent hydrogen, alkyl, haloalkyl, alkenyl, alkynyl, hydroxyalkyl, alkoxyalkyl, cycloalkyl, cycloalkylalkyl, aryl, aralkyl or aminoalkyl radicals or N-mono- or N,N-disubstituzed aminoalkyl radicals, wherein said substituents are alkyl, aryl, aralkyl, cycloalkyl or cycloalkylalkyl radicals;
R4 represents alkyl, haloalkyl, alkenyl, alkynyl, hydroxyalkyl, alkoxyalkyl, cycloalkyl, cycloalkylalkyl, heterocycloalkyl, heternaryl, heterocycloalkylalkyl, aryl, aralkyl, hetenaralkyl, amnioalkyl, or aryl or aralkyl radicals substituted with one or more substituents selected from alkyl, alkoxy, halogen, hydroxy, amino, nitro, cyano, and haloalkyl.

### Claim 12 (depends on 11)

A pharmaceutical composition comprising a compound of claim 11 and a pharamaceutically acceptable carrier.

### Claim 13 (depends on 11)

The compound of claim 11 or a pharmaceutically acceptable salt or ester thereof, wherein t represents either 0 or 1;
R1, R30, R31 and R32 each independently represent hydrogen, —OH, —(CH2)C(O)CH2, —CH2SO2NH2, —CONHCH3, —CON(CH3)2, —CH2C(O)NHCH3, —CH2C(O)N(CH3)2, —CONH2, —C(CH3)2(SH), —C(CH3)2(SCH2), —C(CH3)2(S(O)CH3), —C(CH3)2(S(O)2 CH3), alkyl, alkenyl, alkynyl or aralkyl radicals; or R32 and R33 together with the carbon atoms to which they are attached form a three to six-membered cycloalkyl radical;
R2 represents alkyl, aryl, cycloalkyl, cycloalkylalkyl or aralkyl radicals, which radicals are optionally substituted with halogen, alkyl, —NO2, —CN, —CF3, —OR9 or —SR9 radicals, wherein R9 represents hydrogen or alkyl radicals;
R3represents alkyl, haloalkyl, alkenyl, hydroxyalkly, alkoxyalkl, cycloalkyl, cycloakylalkyl, aryl or aralkyl radicals;
R4 represents alkyl, haloalkyl, alkenyl, alkynyl, hydroxyalkyl, alkoxyalkyl, cycloalkyl, cycloalkylalkyl, heterocycloalkyl, heternaryl, heterocycloalkylalkyl, aryl, aralkyl, heteroaralkyl, amnioalkyl, or aryl or aralkyl radicals substituted with one or more substituents selected from alkyl, alkoxy, halogen, hydroxy, amino, nitro, cyano, and haloalkyl, and
R33 and R34 each represent hydrogen, alkyl, alkenyl, alkynyl, hydroxalkyl, alkoxyalkyl, cycloalkyl, cycloakylalkyl, aryl, aralkyl, or aminoalkyl radicals.

### Claim 14 (depends on 13)

The compound of claim 13, or a pharmaceutically acceptable salt or ester thereof, wherein t is 0;
R1, R30, R31 and R32 each independently represent hydrogen, —OH, —(CH2)C(O)CH2, —CH2SO2NH2, —CONHCH3, —CON(CH3)2, —CH2C(O)NHCH3, —CH2C(O)N(CH3)2, —CONH2, —C(CH3)2(SH), —C(CH3)2(SCH2), —C(CH3)2(S(O)CH3), —C(CH2)2(S(O)2 CH3), alkyl, alkenyl, alkynyl or aralkyl radicals,
R2 represents alkyl, cycloalkylalkyl or aralkyl radicals, which radicals are optionally substituted with halogen, —OR9 or —SR9 radicals, wherein R9 represents hydrogen or methyl radicals;
R3 represents alkyl, cycloalkyl, cycloalkylalkyl, aryl, or aralkyl radicals;
R4 represents heteroaryl, aryl, aralkyl, or aryl or aralkyl radicalc substituted with one or more substituents selected from alkyl, alkoxy, halogen, hydroxy, amino, nitro, cyano, and haloalkyl alkyl or aryl radical; and
R33 and R34 each independently represent hydrogen, alkyl, hydroxyakkyl, alkoxyalkyl, aryl, aralkyl, or aminoalkyl radicals.

### Claim 15 (depends on 14)

The compound of claim 14, or a pharmaceutically acceptable salt or ester thereof, wherein t is 0;
R1 represents hydrogen, alkyl of 1 to 4 carbon atoms, alkenyl of 3 to 8 carbon atoms or aralkyl radicals;
R2 represents alkyl, cycloalkylalkyl or aralkyl radicals, which radicals are optionally substituted with halogen, —O9 or —SR9 radicals, wherein R4 represents hydrogen or methyl radicals;
R3 represents alkyl, cycloalkyl, cycloalkyl alkyl, aryl or aralkyl radicals;
R4 represents heteroaryl, aryl, or aryl substituted with one or more substituents selected from alkoxy, hydroxy, amino, nitro, cyano, and haloalkyl alkyl or aryl radicals;
R30, R31 and R32 each independently represent hydrogen or alkyl radicals; and
R33and R34 each independently represent hydrogen, alkyl, or aminoalkyl radicals.

### Claim 16 (depends on 15)

The compound of claim 15, or a pharmaceutically acceptable salt or ester thereof, wherein t is 0;
R1 represents hydrogen, methyl ethyl, iso-propyl, propargyl, tert-butyl, sec-butyl, benzyl or phenylpropyl radicals;
R2 CH2SCH1CH2—, iso-butyl), n-butyl, benzyl, 4-fluorobenzyl, 2-naphthylmethyl or cyclohexylmethyl radicals;
R3 represents n-pentyl, n-hexyl, n-propyl, i-butyl, neo-pentyl, i-amyl, n-butyl, benzyl, para-fluorobenzyl, para-methoxybenzyl, para-methylbenzyl, 2-naphthylmethyl, cyclohexylmethyl or cyclohexyl radicals;
R4 represent heteroaryl, aryl, or aryl substituted with one or more substituent selected from alkoxy, amino, or nitro radicals;
R30, R31 and R32 each independently represent hydrogen, methyl or ethyl radicals; and
R32 and R33 each independently represent hydrogen, methyl, or methylamino radicals.

### Claim 17 (depends on 16)

The compound of claim 16 which is

### Claim 18 (depends on 1)

A method of inhibiting a retrovirus protease comprising administering a protease inhibiting amount of a composition comprising a compound of claim 1 and a pharmaceutically acceptable carrier.

### Claim 19 (depends on 18)

The method of claim 18 wherein the retrovirus protease is HIV protease.

### Claim 20 (depends on 1)

A method of treating AIDS comprising administering an effective amount of a composition comprising a compound of claim 1 and a pharmaceutically acceptable carrier.
